Retatrutide (60 mg)

What is Retatrutide (60 mg)?

Retatrutide (60 mg) is a synthetic, long-chain peptide designed to interact with multiple hormone-related receptor systems in experimental models. Specifically, Retatrutide is studied as a triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.

By engaging these pathways simultaneously, Retatrutide allows researchers to investigate how coordinated receptor activation impacts glucose metabolism, lipid utilization, appetite regulation, and overall energy balance. This multi-pathway approach enables the study of receptor cross-talk, intracellular signaling, and hormonal feedback mechanisms in controlled research environments.

The 60 mg format is suited for large-scale assays, longitudinal studies, and multi-phase metabolic experiments that require a consistent supply of peptide. All applications are limited to laboratory and preclinical research use.

Product Specifications

• CAS Number: 2381089-83-2
• Synonyms: Retatrutide acetate, LY3437943
• Peptide Sequence:
  Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (Sodium salt)
• Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
• Molecular Weight:33 g/mol
• Subcategory: Weight Loss & Metabolic Peptides
• Purity: ≥95% (verified by HPLC and mass spectrometry)
• Packaging Format: 60 mg lyophilized powder in sealed research-grade vial
• Storage Conditions: Store at 2–8 °C (≤–20 °C for periods of non-use). Protect from light.
• Intended Use: For Laboratory Research Use Only

Key Characteristics of Retatrutide (60 mg)

• Triple Receptor Agonist (Research Context): Designed to engage GLP-1, GIP, and glucagon receptors in experimental systems.
• Integrated Metabolic Modeling: Supports studies evaluating coordinated endocrine signaling rather than isolated receptor activation.
• Structurally Modified for Stability: Contains non-natural amino acids (e.g., Aib residues) and structural elements that enhance peptide stability in laboratory models.
• High Molecular Complexity: A long amino acid sequence enables detailed investigations of receptor binding and intracellular signaling.
• High Analytical Purity: Typically ≥95%, confirmed through chromatographic and spectrometric validation.
• Lyophilized Formulation: Freeze-dried format helps preserve structural integrity before reconstitution.
• Batch Consistency: Manufactured under controlled processes to support reproducible experimental results.

How Retatrutide (60 mg) Supports Research

Retatrutide (60 mg) is used in laboratory settings to study how multi-receptor activation influences metabolic and hormonal signaling networks. By simultaneously activating GLP-1, GIP, and glucagon receptors, it allows researchers to investigate receptor cross-talk, intracellular cascades, and their role in glucose regulation, lipid metabolism, and energy homeostasis.
In experimental models, Retatrutide is applied to study:

• Hormone-receptor binding dynamics
• Intracellular signaling cascades
• Glucose-regulatory pathway activity
• Lipid metabolism and substrate utilization
• Interactions between incretin and glucagon signaling

Retatrutide’s multi-receptor design enables the study of complex metabolic signaling interactions that are not observable when studying single-pathway peptides.

Research Applications & Usage Information

Retatrutide (60 mg) is commonly utilized in:

• GLP-1 receptor signaling studies
• GIP receptor pathway analysis
• Glucagon receptor activation research
• Multi-receptor agonist comparison models
• Endocrine and metabolic systems research
• Cellular second-messenger and downstream pathway assays
• Preclinical metabolic modeling in animal studies

All applications are investigational and confined to controlled laboratory environments.

Handling and Storage Recommendations

• Store unopened vials at 2–8 °C. For extended preservation, maintain at ≤–20 °C. Protect from light.
• Keep vial sealed until reconstitution.
• Minimize exposure to moisture and direct light.
• Allow vial to equilibrate before opening to prevent condensation.
• After reconstitution, store solutions at 2–8 °C per laboratory protocol.
• Avoid repeated freeze-thaw cycles to preserve peptide stability.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013
2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
3. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. doi:10.1038/s41591-024-03018-2
4. Ma J, Hu X, Zhang W, Tao M, Wang M, Lu W. Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. Endocrine. 2025;87(1):159-169. doi:10.1007/s12020-024-03998-8